ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2016

Jan 5, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2015-12-30

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-12-30	Common Stock	F	58712	$6.13	Disposed	561461	Direct
2016-01-01	Common Stock	A	540000	$0.00	Acquired	1101461	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-01	Stock Options	$6.15	A	80000	Acquired	2026-01-01	Common Stock (80000)	Direct

Footnotes

F1: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of certain predetermined performance goals related to the advancement of the Company's clinical programs and business development over three years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.

F2: Option vests and becomes exercisable over a four year period from date of grant.